ArticleJournal of gastrointestinal cancer2025
Predictive Factors for Esophageal Stricture Following Definitive Chemoradiotherapy in Esophageal Carcinoma.
Article in Journal of gastrointestinal cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Advances in the treatment of postoperative anastomotic strictures in esophageal cancer a comparative analysis of the efficacy of endoscopic versus interventional dilatation.Langenbeck's archives of surgery · 2026Review
- Dual Endoscopic Approach for Radiation-Induced Complete Esophageal Obstruction in the Upper Esophagus: Insights From 2 Challenging Cases.ACG case reports journal · 2026Article
- Predictors of Post-Definitive Chemoradiotherapy Esophageal Stricture in T2-T4 Esophageal Squamous Cell Carcinoma: : A Single-Center Retrospective Study.Journal of gastrointestinal cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeConcurrent Chemo-radiotherapy (CRT) offers attractive approaches providing the opportunity of cure, as well as organ preservation for patients with esophageal cancer and has now become the standard treatment for locally advanced unresectable esophageal cancers. However, one of the major concerns associated with CRT is the potential for treatment-related side effects, including strictures and fistula formation. This study aims to identify the predictors of stricture formation following definitive CRT in esophageal carcinoma. MATERIALS AND
methods79 patients who underwent definitive CRT for carcinoma esophagus, post cricoid area and gastro-esophageal junction (GEJ), from 2013 to 2023 were included in the study. The medical records of these patients were reviewed to collect data including the following parameters: age, gender, grade of dysphagia at presentation, stage of the disease, circumferential involvement by disease, treatment technique used, dose of radiation, and concurrent chemotherapy used. These factors were then correlated to development of radiation induced stricture.
resultThe median follow-up period was 22.5 months in survivors. Median overall survival was 47 months. The post-treatment stricture occurred in 22 patients (27.85%). The median time to develop a stricture after completing treatment was 4.5 months. In multivariate analysis, factors significantly correlated with post treatment stenosis were stage T4 (P = 0.012) and concurrent chemotherapy with carboplatin and paclitaxel (p=0.034). Other factors like patient age, sex, stage group, length of the involved segment, maximum tumor thickness, RT technique, and radiation dose were not associated with stricture risk.
conclusionThis study suggested that patients with T4 stage and patients receiving concurrent carboplatin and paclitaxel chemotherapy have higher risk of developing treatment-related esophageal stenosis.
Indexed as
Identifiers
39953181What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.